We use cookies to analyze site usage and improve your experience. You can accept all, reject non-essential, or customize. See our Privacy Policy.
HRT & Sexual Health · All 50 States
Genitourinary syndrome of menopause and low desire, treated in order: vaginal estrogen first, systemic HRT for whole-body symptoms, DHEA and ospemifene, and where testosterone genuinely fits.
Start your visit — $79/mo →← Hormone replacement therapy pillar
DIRECT ANSWER
Treat pain before desire. Vaginal estrogen is the most effective treatment for dryness, painful sex, and recurrent urinary tract infections, it works with minimal systemic absorption, and it can be used indefinitely and alongside systemic HRT. Once pain, dryness, and sleep are handled, persistent distressing low desire is the one indication with randomized support for physiologic-dose testosterone in postmenopausal women.
First-line and highly effective; minimal systemic absorption; usable long-term.
Read more →A non-estrogen prescription option for moderate-to-severe painful sex.
Add when hot flashes, sleep, or mood are also involved; layer local estrogen on top if dryness persists.
Read more →Considered for persistent distressing low desire after estrogen is optimized; off-label in the U.S.
Read more →Useful adjuncts for comfort; they do not reverse the underlying tissue change.
| Week 2–3 | Dryness and irritation ease during the loading phase of local estrogen. |
| Week 8–12 | Tissue thickness, elasticity, and pain with sex meaningfully improve. |
| Month 3+ | If desire remains low despite comfortable, pain-free sex, testosterone is discussed. |
Low-dose vaginal estrogen produces minimal systemic absorption and is generally continued indefinitely, since symptoms return when it is stopped. Guideline bodies support long-term use, and its use in breast cancer survivors is decided with the treating oncologist.
Often yes, by removing the obstacles — pain, dryness, poor sleep, hot flashes, and low mood. Estrogen is not a direct desire drug; for a subset of women, added physiologic-dose testosterone is what closes the gap.
No. Local vaginal estrogen alone is the appropriate treatment when symptoms are confined to the genitourinary tract.
Yes. It restores vaginal pH and the protective microbiome and reduces recurrent urinary tract infections in postmenopausal women.
Intake takes about ten minutes. A clinician licensed in your state reviews it within one business day and builds a plan around the symptom that is actually bothering you.
Start your visit — $79/mo →Comparing providers? How to choose an HRT telehealth provider →
WRITTEN & MEDICALLY REVIEWED BY
Kindr Health Inc. — Editorial & Clinical Team (physician-supervised)
Kindr’s clinical content is written and reviewed by board-certified clinicians who prescribe hormone therapy every day across all 50 states — menopause-focused physicians, nurse practitioners, and pharmacists working under Kindr Health, Inc.’s organizational clinical oversight. Every page is checked against current NAMS and ACOG guidance, FDA labeling, and the primary literature before publication, then re-reviewed on a rolling schedule when guidance changes.
Organizational NPI 1609792902 · Last reviewed July 3, 2026 · Editorial policy
Educational content only — not a substitute for individual medical advice, diagnosis, or treatment.
SOURCES & REFERENCES
Information on this page is for educational purposes only. Prescription medications require clinical evaluation and provider approval. Individual results vary. Not an emergency service.